Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • NGSfan
    Senior Member
    • Apr 2009
    • 181

    Agilent SureSelect - coverage of high GC regions

    We have successfully run a targeted enrichment with SureSelect and were able to achieve similar results to the Tewhey et al (2009 Genome Biol) for our own targeted subset. As shown in their paper, we also noticed that regions of high GC content were difficult to capture - we see lower read coverage in these areas. Does anyone have any experience trying to increase the coverage of these more difficult regions? Say, for example, by increasing the number of baits overlapping a high GC region?

    We are wondering if this is a worthwhile approach and if by chance anyone has tried it already with useful results. We have some extra design space on our SureSelect and are considering "piling on" the baits in these regions for a few important genes.
  • krobison
    Senior Member
    • Nov 2007
    • 734

    #2
    I would be very interested in how you fare with this.

    One possible explanation for dropout of extremes of %GC is not so much the SureSelect hybridization but the various PCR steps. Do you think you could significantly shave the total number of PCR cycles the library is exposed to?

    Comment

    • Xi Wang
      Senior Member
      • Oct 2009
      • 317

      #3
      Originally posted by NGSfan View Post
      We have successfully run a targeted enrichment with SureSelect and were able to achieve similar results to the Tewhey et al (2009 Genome Biol) for our own targeted subset. As shown in their paper, we also noticed that regions of high GC content were difficult to capture - we see lower read coverage in these areas. Does anyone have any experience trying to increase the coverage of these more difficult regions? Say, for example, by increasing the number of baits overlapping a high GC region?

      We are wondering if this is a worthwhile approach and if by chance anyone has tried it already with useful results. We have some extra design space on our SureSelect and are considering "piling on" the baits in these regions for a few important genes.
      How do you define the sequence coverage? If you take log values of the coverage, what is the results?
      Xi Wang

      Comment

      • upenn_ngs
        Member
        • Sep 2009
        • 70

        #4
        The drop in high-GC content is largely from secondary structure formation. Adding formamide and increasing the temperature might tilt the table toward hybridization with RNA oligo.

        Comment

        • NGSfan
          Senior Member
          • Apr 2009
          • 181

          #5
          Originally posted by krobison View Post
          I would be very interested in how you fare with this.

          One possible explanation for dropout of extremes of %GC is not so much the SureSelect hybridization but the various PCR steps. Do you think you could significantly shave the total number of PCR cycles the library is exposed to?

          For the PCR steps, I mostly worry over "PCR duplicates". And if I remember, wouldn't the PCR bias the coverage in favor of high GC?

          Novel sequencing technologies permit the rapid production of large sequence data sets. These technologies are likely to revolutionize genetics and biomedical research, but a thorough characterization of the ultra-short read output is necessary. We generated and analyzed two Illumina 1G ultra-short r …

          Comment

          • NGSfan
            Senior Member
            • Apr 2009
            • 181

            #6
            Originally posted by Xi Wang View Post
            How do you define the sequence coverage? If you take log values of the coverage, what is the results?
            Good question - I am just doing this "by eye" so to speak. So for example, the average bp coverage of a target region is 20X and then drops to 2 or 0 in high GC regions.

            Comment

            • NGSfan
              Senior Member
              • Apr 2009
              • 181

              #7
              Originally posted by upenn_ngs View Post
              The drop in high-GC content is largely from secondary structure formation. Adding formamide and increasing the temperature might tilt the table toward hybridization with RNA oligo.
              The secondary structure issue would be my guess as well. My only concern with adding formamide and/or increasing the temp is the effect on lower GC targets. I like the idea, but shifting the binding energies might cause as many problems as it solves.

              The idea of adding more baits was to help increase coverage of a subset of targets without affecting the enrichment of other targets.

              Comment

              • upenn_ngs
                Member
                • Sep 2009
                • 70

                #8
                Another factor, many GC rich regions are dropped from both whole genome sequencing as well as the exome capture. This image from the Broad.

                Last edited by upenn_ngs; 02-17-2010, 08:05 AM.

                Comment

                • Xi Wang
                  Senior Member
                  • Oct 2009
                  • 317

                  #9
                  Originally posted by NGSfan View Post
                  Good question - I am just doing this "by eye" so to speak. So for example, the average bp coverage of a target region is 20X and then drops to 2 or 0 in high GC regions.
                  I guess if you take log value of the bp coverage for each region, and then take the average, the phenomenon will be different. I am just wondering the amplification is exponentially increased the DNA fragments.
                  Xi Wang

                  Comment

                  • dottomarco
                    Member
                    • Jul 2009
                    • 32

                    #10
                    Originally posted by NGSfan View Post
                    We have successfully run a targeted enrichment with SureSelect and were able to achieve similar results to the Tewhey et al (2009 Genome Biol) for our own targeted subset.
                    @ NGSfan : What sequencer did you use? Illumina GA II?
                    I am interested in using Agilent's SureSelect for sequence enrichment to get the targets to sequence with a 454 FLX. Do you think using a long fragmented 454 library with SureSelect can create any problem with the hybridization? Agilent do not provide any ufficial protocol for 454 libraries, but I assume that their long baits could work well with our ~400-500 bp fragments.

                    Comment

                    • krobison
                      Senior Member
                      • Nov 2007
                      • 734

                      #11
                      The main platform-customization of the SureSelect as I understand it is there are blocking oligos to prevent daisy-chaining of products -- without these sometimes a correctly hybridized fragment will hybridize to an off-target fragment via the adapter regions.

                      Comment

                      • NGSfan
                        Senior Member
                        • Apr 2009
                        • 181

                        #12
                        Originally posted by Xi Wang View Post
                        I guess if you take log value of the bp coverage for each region, and then take the average, the phenomenon will be different. I am just wondering the amplification is exponentially increased the DNA fragments.
                        Yes, that is a good point. Amplification is a concern and will certainly bias things. However, I am not seeing PCR duplicates to be a big issue in my data set.

                        I have talked to some big sequencing centers about the GC issue and they also have encountered it, however their approach is to simply bump up the sequencing - to 70X coverage (we are at 30-40X).

                        I should have mentioned we did single end reads. We should be getting paired end reads soon, and I hope this might help a little, since we'll be able to sequence a GC-rich region which was partially bound at the other end with an average GC content. Maybe?
                        Last edited by NGSfan; 03-11-2010, 04:59 AM.

                        Comment

                        • NGSfan
                          Senior Member
                          • Apr 2009
                          • 181

                          #13
                          Originally posted by dottomarco View Post
                          @ NGSfan : What sequencer did you use? Illumina GA II?
                          I am interested in using Agilent's SureSelect for sequence enrichment to get the targets to sequence with a 454 FLX. Do you think using a long fragmented 454 library with SureSelect can create any problem with the hybridization? Agilent do not provide any ufficial protocol for 454 libraries, but I assume that their long baits could work well with our ~400-500 bp fragments.
                          Their long baits ~120bp are quite reasonable - but I have no clue on the behavior of hybridization when having longer fragments (400-500). I suspect you might run into self-hybridizing issues more often, but who really knows!

                          We generally followed the Agilent protocol - fragmenting ~200bp . Something to note: if you are after exons, then you don't want too long a fragment because you'll be sequencing at the ends and your aligned reads will be more often "off target" so to speak - in the sense that they will be around the exon, rather than on the exon.

                          Comment

                          • Xi Wang
                            Senior Member
                            • Oct 2009
                            • 317

                            #14
                            Originally posted by NGSfan View Post
                            Yes, that is a good point. Amplification is a concern and will certainly bias things. However, I am not seeing PCR duplicates to be a big issue in my data set.

                            I have talked to some big sequencing centers about the GC issue and they also have encountered it, however their approach is to simply bump up the sequencing - to 70X coverage (we are at 30-40X).

                            I should have mentioned we did single end reads. We should be getting paired end reads soon, and I hope this might help a little, since we'll be able to sequence a GC-rich region which was partially bound at the other end with an average GC content. Maybe?
                            Oh. But if you have the data, you can try what just I mentioned.

                            And for PE reads, I don't think it can improve a lot. Because it is the DNA fragments that amplified. So the coverage should have some relationship with the GC-content of the DNA fragments. On the other hand, the read GC-content and the DNA fragment GC-content have a high correlation. As a result, the relationship between the read GC-content and the coverage reflects a lot the reality.
                            Xi Wang

                            Comment

                            • bioinfosm
                              Senior Member
                              • Jan 2008
                              • 483

                              #15
                              Another point which I did not notice here is, # of reads actually sequenced to get 30x exome coverage for the agilent capture stuff.

                              We notice that only 20% of reads map on-target! Is that a common thing? (Illumina 75bp PE)
                              --
                              bioinfosm

                              Comment

                              Latest Articles

                              Collapse

                              • SEQadmin2
                                Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
                                by SEQadmin2


                                Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

                                The systematic characterization of the human proteome has
                                ...
                                07-20-2026, 11:48 AM
                              • SEQadmin2
                                Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
                                by SEQadmin2



                                Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
                                ...
                                07-09-2026, 11:10 AM
                              • SEQadmin2
                                Cancer Drug Resistance: The Lingering Barrier to Rising Survival
                                by SEQadmin2



                                Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

                                There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
                                07-08-2026, 05:17 AM

                              ad_right_rmr

                              Collapse

                              News

                              Collapse

                              Topics Statistics Last Post
                              Started by SEQadmin2, 07-24-2026, 12:17 PM
                              0 responses
                              29 views
                              0 reactions
                              Last Post SEQadmin2  
                              Started by SEQadmin2, 07-23-2026, 11:41 AM
                              0 responses
                              21 views
                              0 reactions
                              Last Post SEQadmin2  
                              Started by SEQadmin2, 07-20-2026, 11:10 AM
                              0 responses
                              211 views
                              0 reactions
                              Last Post SEQadmin2  
                              Started by SEQadmin2, 07-13-2026, 10:26 AM
                              0 responses
                              78 views
                              0 reactions
                              Last Post SEQadmin2  
                              Working...